New pill shrinks lung tumors before surgery in early trial
NCT ID NCT07274761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a pill called sunvozertinib given before surgery to people with a certain type of lung cancer (stage II-IIIB non-small cell lung cancer with EGFR exon 20 insertion mutations). The goal is to see if the drug can shrink tumors and improve surgical outcomes. About 24 participants will receive the drug and be monitored for response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?